3.71
+0.33(+9.76%)
Currency In USD
| Previous Close | 3.38 |
| Open | 3.44 |
| Day High | 3.98 |
| Day Low | 3.39 |
| 52-Week High | 7.52 |
| 52-Week Low | 1.11 |
| Volume | 2.82M |
| Average Volume | 1.46M |
| Market Cap | 72.99M |
| PE | -2.59 |
| EPS | -1.43 |
| Moving Average 50 Days | 2.2 |
| Moving Average 200 Days | 2.19 |
| Change | 0.33 |
If you invested $1000 in Annovis Bio, Inc. (ANVS) since IPO date, it would be worth $386.86 as of November 20, 2025 at a share price of $3.71. Whereas If you bought $1000 worth of Annovis Bio, Inc. (ANVS) shares 3 years ago, it would be worth $286.49 as of November 20, 2025 at a share price of $3.71.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
GlobeNewswire Inc.
Nov 18, 2025 1:00 PM GMT
MALVERN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
GlobeNewswire Inc.
Nov 17, 2025 1:00 PM GMT
Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology showing a three-times greater response New data demonstrate reductions in plasma biomarkers pTau217, total tau, and brain-derived
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program
GlobeNewswire Inc.
Nov 06, 2025 1:00 PM GMT
All 84 clinical sites across the U.S. are fully activated, enrolling, and treating patients The first group of participants reached the 6-month treatment milestone The study is now 25% complete, keeping Annovis on track for data readout MALVERN, Pa.,